|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.34 - 17.88|
|52 Week Range||8.50 - 24.43|
|PE Ratio (TTM)||2.60|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.03|
The narrative surrounding Broadcom Inc (NASDAQ:AVGO) certainly has changed in a hurry. A steady diet of M&A and solid organic growth made AVGO one of the more widely praised stocks in all of tech. AVGO stock has fallen 20% from late November highs, with a nearly 10% drop in just the last few sessions amid concerns about the semiconductor sector.
From a headline standpoint, Allergan plc (NYSE:AGN) stock does look attractive at the moment. A steady pullback has seen Allergan stock fall about 35% from late July highs and Allergan has dropped by half from 2015 levels. A sub-10x forward EPS multiple is notably cheaper than those assigned to rivals like Pfizer Inc. (NYSE:PFE) and Merck & Co., Inc. (NYSE:MRK).
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Valeant Pharmaceuticals International Inc (NYSE:VRX) with a market-capitalization of US$6.05B, rarely draw their attention. Despite this, theRead More...
LAVAL, Quebec, April 19, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International (NYSE/TSX: VRX), announced today that its ONE by ONE Recycling Program, the first contact lens recycling program of its kind, has recycled nearly 2.5 million used contact lenses, blister packs and top foils since the program launched in November 2016, diverting more than 14,000 pounds of waste from landfills —about the weight of a small aircraft.1 The program is made possible through a collaboration with TerraCycle®, a world leader in the collection and repurposing of hard-to-recycle post-consumer waste. "Previously, contact lenses and lens packaging materials were filtered out at standard recycling centers due to their small sizes.
NEW YORK, NY / ACCESSWIRE / April 16, 2018 / U.S. equities plunged on Friday, but finished the week on a positive note, as bank earnings failed to lift market optimism amidst geopolitical anxiety. The ...
Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International’s insiders have invested more than 7 million shares in the within the past three months. Generally, insiders buying more shares in their ownRead More...
Valeant Pharmaceuticals International Inc. keeps showing up next to the names of struggling investors.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.
LAVAL, Quebec , April 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Valeant Pharmaceuticals International, a wholly owned ...
LAVAL, Quebec, April 12, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that the Arbitral Tribunal issued a decision (rendered on April 9, 2018) relating to the arbitration between Santarus Inc. and Valeant Pharmaceuticals Ireland (collectively "Valeant"), and Cosmo Technologies Ltd. and Cosmo Technologies III Ltd. (collectively, "Cosmo"), the licensor of certain intellectual property rights in, and supplier of, Valeant's UCERIS® extended release tablets. The arbitration focused on Cosmo's allegations that Valeant had breached the License Agreement and Manufacturing and Supply Agreement (collectively the "Agreements") between the parties and Cosmo's claim that it had validly terminated the Agreements.
More than 20 Podium Presentations, Posters and Films to be Featured LAVAL, Quebec , April 11, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant ...
LAVAL, Quebec , April 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") announced today the expiration of the cash tender offers (the "Tender ...
According to the terms of the agreement, Kaken Pharmaceutical granted an exclusive license to Valeant Pharmaceuticals for the development and commercialization of products containing KP-470 for the treatment of dermatological and rheumatological disorders in the United States, Canada, Western Europe, and Eastern Europe. In January 2018, Valeant Pharmaceuticals’ subsidiary Bausch & Lomb announced that the European Commission granted a CE mark for the Stellaris Elite vision enhancement system. Nineteen analysts are tracking Valeant Pharmaceuticals in April 2018.
In 4Q17, Valeant Pharmaceuticals International’s (VRX) Xifaxan generated revenues of $275 million, compared to $251 million in 4Q16. That was a 10% growth on a YoY (year-over-year) basis and a 4% decline quarter-over-quarter.
In 4Q17, Valeant Pharmaceuticals International’s (VRX) Wellbutrin generated revenues of $67 million, a 10% growth on a quarter-over-quarter basis. In 4Q17, Wellbutrin’s YoY (year-over-year) growth was flat.
In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.
In 4Q17, Valeant Pharmaceuticals International’s (VRX) U.S Diversified Products generated revenues of $335 million compared to $398 million in 4Q16, a 16% decline on a YoY (year-over-year) basis.
In 4Q17, Soflens, a product of Valeant Pharmaceuticals International’s (VRX) subsidiary Bausch & Lomb, reported revenues of $78 million compared to $79 million in 4Q16. That was a 1% decline on a YoY (year-over-year) basis and a 6% decline quarter-over-quarter.
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
In 4Q17, Valeant Pharmaceuticals’ (VRX) subsidiary Bausch & Lomb reported revenues of $1.2 billion compared to $1.3 billion in 4Q16. That was a 3% growth on a YoY (year-over-year) basis and a 2% growth quarter-over-quarter.
Studies 1 and 2, which enrolled a total of 418 patients, showed DUOBRII was consistently more effective than vehicle in achieving treatment success (defined as those with at least a two-grade improvement from baseline in an Investigator Global Assessment (IGA) score, and 'clear' or 'almost clear' skin), demonstrating statistically significant superiority by week four (in Study 1) and week two (in Study 2). At week eight, 35.8 percent (Study 1) and 45.3 percent (Study 2) had achieved the primary efficacy outcome, compared to 7.0 percent and 12.5 percent on vehicle (both p